PHILADELPHIA, March 31, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") has scheduled a conference call and audio webcast on Wednesday, April 6, 2011 at 10:00 AM Eastern Time. The conference call will discuss its year-end 2010 results of operations and will also focus on new clinical initiatives against the backdrop of recent advances in the cancer immunotherapy sector and new advances in CFS diagnostics. Company executives will conduct a question and answer session following their remarks.
| To access the conference call: |
| U.S. Callers: 800-346-7359 |
| International Callers: 973-528-0008 |
| Conference Entry Code: 27781 |
This call will be webcast via the Company's website at: http://www.hemispherx.net.
The webcast and a digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until April 20, 2011 by dialing:
| U.S. Callers: 800-332-6854 |
| International Callers: 973-528-0005 |
| Conference Entry Code: 27781 |
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of pre-clinical or clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications.